



No Evidence for Acquired Mutations Associated with Cytochrome *bc*₁ Inhibitor Resistance in 13,559 Clinical *Mycobacterium tuberculosis* Complex Isolates

Jan Rybniker,^{a,b,c} Thomas Andreas Kohl,^{d,e} Ivan Barilar,^{d,e} Stefan Niemann^{d,e}

^aDepartment of Internal Medicine, University Hospital of Cologne, Cologne, Germany

^bGerman Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany

^cCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany

^dMolecular and Experimental Mycobacteriology, Priority Area Infections, Research Center Borstel, Borstel, Germany

^eGerman Center for Infection Research, TTU-TB, Borstel, Germany

KEYWORDS *Mycobacterium tuberculosis*, cytochrome *bc*₁, lansoprazole, multidrug resistance, proton pump inhibitor

In 2017, tuberculosis (TB), caused by *Mycobacterium tuberculosis*, was responsible for an estimated 1.6 million deaths (1). The control of this pandemic is threatened because of a strong increase of multidrug-resistant *M. tuberculosis* (MDR-TB) (2). This emergence of difficult-to-treat strains requires the development of safe drugs with new mechanisms of action. A highly promising drug target is the cytochrome *bc*₁ complex of the mycobacterial respiratory chain. Several chemically diverse cytochrome *bc*₁ inhibitors with excellent antituberculous activity were identified in the past 5 years (3–9). One of these inhibitors is lansoprazole sulfide (LPZS), a close analogue and metabolite of the blockbuster drug lansoprazole (Prevacid), a gastric proton-pump inhibitor (PPI) (3). Mode-of-action studies revealed that lansoprazole targets cytochrome *bc*₁ after prodrug conversion to LPZS in the host cell. Data on LPZS and its parent compound lansoprazole were recently exploited in a cohort study analyzing the incidence of TB among individuals taking lansoprazole for the treatment of gastric acid-related diseases (10). Lansoprazole is among the most widely sold drugs in the world, which enabled the evaluation of primary care patient records derived from the United Kingdom Practice Research Datalink (CPRD) (10). Intriguingly, this study demonstrated a statistically significant protective association between lansoprazole use and newly diagnosed TB disease. This is a surprising observation, since antimycobacterial activity of lansoprazole requires its conversion to LPZS. LPZS plasma concentrations during lansoprazole treatment are relatively low and may not exceed the *in vitro* MIC determined for *M. tuberculosis* (11). Nevertheless, the effect observed seems to be specific for lansoprazole and the antimycobacterial activity of lansoprazole analogues, since antacid treatment with two other PPIs (omeprazole and pantoprazole) was not protective against TB infection. Omeprazole and pantoprazole provided excellent controls in this study, since neither of the drugs possesses antimycobacterial activity due to structural restrictions (3).

These clinical data raise concerns on the susceptibility of clinical *M. tuberculosis* isolates to LPZS and other cytochrome *bc*₁ inhibitors. Single-agent therapy and suboptimal dosing are well-known drivers of antibiotic resistance, as demonstrated for acquired fluoroquinolone resistance in *M. tuberculosis* isolates, which was associated with the receipt of fluoroquinolones prior to the TB diagnosis (12, 13). Widespread use of lansoprazole may have already selected for resistant strains, which would in turn hamper future clinical exploitation of these drugs in the fight against MDR-TB.

For this reason, we investigated cytochrome *bc*₁ inhibitor resistance mutations in *M. tuberculosis* complex (MTC) whole-genome data derived from clinical isolates. Resistance in most cytochrome *bc*₁ inhibitors identified so far is caused by single nucleotide

Citation Rybniker J, Kohl TA, Barilar I, Niemann S. 2019. No evidence for acquired mutations associated with cytochrome *bc*₁ inhibitor resistance in 13,559 clinical *Mycobacterium tuberculosis* complex isolates. *Antimicrob Agents Chemother* 63:e01317-18. <https://doi.org/10.1128/AAC.01317-18>.

Copyright © 2018 Rybniker et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Jan Rybniker, jan.rybniker@uk-koeln.de, or Stefan Niemann, sniemann@fz-borstel.de.

Accepted manuscript posted online 15 October 2018

Published 21 December 2018

TABLE 1 Phylogenetic lineages of *Mycobacterium tuberculosis* complex strains screened for cytochrome *bc₁* inhibitor resistance-associated mutations

MTC phylogenetic lineage ^a	No. of strains
East African, Indian (1)	424
East Asian, Beijing (2)	4,017
Delhi-CAS (3)	922
Euro-American (4)	7,537
West Africa, 1 (5)	183
West Africa, 2 (6)	192
Ethiopia (7)	7
Animal pathogens	265
<i>M. canettii</i>	12

^aNumbers in parentheses indicate the lineage number (14).

polymorphisms (SNPs) of *qcrB* (Rv2196), causing mutations in the ubiquinol oxidation (QP) site of mycobacterial cytochrome *bc₁* (3–5, 9).

A total of 13,559 MTC next-generation sequencing data sets were analyzed with the MTBseq pipeline, i.e., reads were mapped to the H37Rv reference genome (GenBank identifier [ID], [NC_000962.3](https://www.ncbi.nlm.nih.gov/nuccore/NC_000962.3)) with the alignment program BWA, and mappings were refined and processed with the GATK and SAMtools toolkits (15). The samples were derived from both prospective and targeted collections of isolates and originated from countries around the world, with the vast majority of samples collected between 2010 and 2018. The collection contains strains from all lineages of the MTC (Table 1). For variant detection in mapped reads, we used the MTBseq default minimum thresholds of at least 4 reads coverage in both forward and reverse orientations, at least 4 reads calling the allele with at least a Phred score of 20, and 75% allele frequency (https://github.com/ngs-fzb/MTBseq_source). All data sets reached at least a mean coverage depth of 50-fold, with at least 95% of the reference genome covered with sufficient quality to meet variant detection thresholds.

Among all detected variants, we screened for any nonsynonymous SNP in codons 176, 182, 312, 313, 317, 342, and 396 of the *qcrB* gene (L176X, S182X, W312X, T313A, A317X, M342X, and A396X, respectively).

Among the 13,559 MTC genomes, there was only one *Mycobacterium bovis* strain which contained a T313A mutation causing resistance to Q203, a cytochrome *bc₁* inhibitor under investigation in clinical trials (9). For the remaining 13,558 MTC genomes, we detected wild-type sequences for the above-mentioned *qcrB* codons.

Our observations clearly show that extensive and worldwide use of proton pump inhibitors in the past decades did not lead to high prevalence of cytochrome *bc₁* resistance mutations in a representative number of clinical MTC isolates. This indicates that further clinical development of these promising antibiotics should not be compromised by prior lansoprazole treatment of people infected with *M. tuberculosis*.

ACKNOWLEDGMENTS

J.R. received funding from the Thematic Translational Unit Tuberculosis (TTU TB; grant numbers TTU 02.806 and 02.905) of the German Center of Infection Research (DZIF). Financial support was also received from the German Research Foundation (DFG RY 159) and the Center for Molecular Medicine Cologne (ZMMK–CAP8). Parts of this work were funded by the European Community's Seventh Framework Program (FP7/2007–2013) under grant agreement 278864 in the framework of the Patho-NGen-Trace project, the Leibniz Science Campus Evolutionary Medicine of the Lung (EvoLUNG), the Wellcome Trust/Newton Fund–MRC Collaborative Award, and the Bill & Melinda Gates Foundation.

REFERENCES

- World Health Organization. 2018. Global tuberculosis report. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global_report/en/.
- Zignol M, Dean AS, Falzon D, van Gemert W, Wright A, van Deun A, Portaels F, Laszlo A, Espinal MA, Pablos-Mendez A, Bloom A, Aziz MA, Weyer K, Jaramillo E, Nunn P, Floyd K, Raviglione MC. 2016. Twenty years

- of global surveillance of antituberculosis-drug resistance. *N Engl J Med* 375:1081–1089. <https://doi.org/10.1056/NEJMSr1512438>.
3. Rybnikier J, Vocat A, Sala C, Busso P, Pojer F, Benjak A, Cole ST. 2015. Lansoprazole is an antituberculous prodrug targeting cytochrome *bc₁*. *Nat Commun* 6:7659. <https://doi.org/10.1038/ncomms8659>.
 4. Arora K, Ochoa-Montaño B, Tsang PS, Blundell TL, Dawes SS, Mizrahi V, Bayliss T, Mackenzie CJ, Cleghorn LAT, Ray PC, Wyatt PG, Uh E, Lee J, Barry CE, III, Boshoff HI. 2014. Respiratory flexibility in response to inhibition of cytochrome *c* oxidase in *Mycobacterium tuberculosis*. *Antimicrob Agents Chemother* 58:6962–6965. <https://doi.org/10.1128/AAC.03486-14>.
 5. Phummarin N, Boshoff HI, Tsang PS, Dalton J, Wiles S, Barry Rd CE, Copp BR. 2016. SAR and identification of 2-(quinolin-4-yloxy)acetamides as *Mycobacterium tuberculosis* cytochrome *bc₁* inhibitors. *Medchemcomm* 7:2122–2127. <https://doi.org/10.1039/C6MD00236F>.
 6. Cleghorn LAT, Ray PC, Odingo J, Kumar A, Wescott H, Korkegian A, Masquelin T, Lopez Moure A, Wilson C, Davis S, Huggett M, Turner P, Smith A, Epemolu O, Zuccotto F, Riley J, Scullion P, Shishikura Y, Ferguson L, Rullas J, Guijarro L, Read KD, Green SR, Hipskind P, Parish T, Wyatt PG. 2018. Identification of morpholino thiophenes as novel *Mycobacterium tuberculosis* inhibitors, targeting QcrB. *J Med Chem* 61:6592–6608. <https://doi.org/10.1021/acs.jmedchem.8b00172>.
 7. Subtil FT, Villela AD, Abadi BL, Rodrigues-Junior VS, Bizarro CV, Timmers LFSM, de Souza ON, Pissinate K, Machado P, López-Gavín A, Tudó G, González-Martín J, Basso LA, Santos DS. 2018. Activity of 2-(quinolin-4-yloxy)acetamides in *Mycobacterium tuberculosis* clinical isolates and identification of their molecular target by whole-genome sequencing. *Int J Antimicrob Agents* 51:378–384. <https://doi.org/10.1016/j.ijantimicag.2017.08.023>.
 8. Chandrasekera NS, Berube BJ, Shetye G, Chettiar S, O'Malley T, Manning A, Flint L, Awasthi D, Ioerger TR, Sacchetti J, Masquelin T, Hipskind PA, Odingo J, Parish T. 2017. Improved phenoxyalkylbenzimidazoles with activity against *Mycobacterium tuberculosis* appear to target QcrB. *ACS Infect Dis* 3:898–916. <https://doi.org/10.1021/acsinfecdis.7b00112>.
 9. Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim S-A, Nam J, Kang H, Kwon H, Oh C-T, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SPS, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han S-J, No Z, et al. 2013. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. *Nat Med* 19:1157–1160. <https://doi.org/10.1038/nm.3262>.
 10. Yates TA, Tomlinson LA, Bhaskaran K, Langan S, Thomas S, Smeeth L, Douglas IJ. 2017. Lansoprazole use and tuberculosis incidence in the United Kingdom Clinical Practice Research Datalink: a population based cohort. *PLoS Med* 14:e1002457. <https://doi.org/10.1371/journal.pmed.1002457>.
 11. Mdanda S, Baijnath S, Shobo A, Singh SD, Maguire GEM, Kruger HG, Arvidsson PI, Naicker T, Govender T. 2017. Lansoprazole-sulfide, pharmacokinetics of this promising anti-tuberculous agent. *Biomed Chromatogr* 31:e0435. <https://doi.org/10.1002/bmc.4035>.
 12. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-West M, Merz WG, Bishai WR, Sterling TR. 2003. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. *Clin Infect Dis* 37:1448–1452. <https://doi.org/10.1086/379328>.
 13. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, Mitchel E, Sterling TR. 2009. Fluoroquinolone resistance in *Mycobacterium tuberculosis*: the effect of duration and timing of fluoroquinolone exposure. *Am J Respir Crit Care Med* 180:365–370. <https://doi.org/10.1164/rccm.200901-0146OC>.
 14. Gagneux S. 2018. Ecology and evolution of *Mycobacterium tuberculosis*. *Nat Rev Microbiol* 16:202–213. <https://doi.org/10.1038/nrmicro.2018.8>.
 15. Kohl TA, Utpatel C, Schleusener V, De Filippo MR, Beckert P, Cirillo DM, Niemann S. 2018. MTBseq: a comprehensive pipeline for whole genome sequence analysis of *Mycobacterium tuberculosis* complex isolates. *PeerJ* 6:e5895. <https://doi.org/10.7717/peerj.5895>.